Demexiptiline
Demexiptiline
Demexiptiline (pronounced: /dɛmɛksɪptɪliːn/) is a tricyclic antidepressant (TCA) that was developed in the 1960s but was never marketed. It is structurally related to other tricyclic antidepressants like imipramine and desipramine.
Etymology
The term "Demexiptiline" is derived from the chemical structure of the compound, which is a derivative of the tricyclic antidepressant class. The prefix "Dem" is an abbreviation of the chemical name, while "exiptiline" is a common suffix used in the naming of tricyclic antidepressants.
Pharmacology
Demexiptiline acts by inhibiting the reuptake of norepinephrine and serotonin, two neurotransmitters in the brain. This increases the concentration of these neurotransmitters in the synaptic cleft, leading to increased neurotransmission and ultimately an antidepressant effect.
Related Terms
- Tricyclic antidepressant: A class of drugs that Demexiptiline belongs to. They are named for their three-ring chemical structure.
- Norepinephrine: A neurotransmitter in the brain that is increased by Demexiptiline.
- Serotonin: Another neurotransmitter that is increased by Demexiptiline.
- Imipramine: A tricyclic antidepressant that is structurally related to Demexiptiline.
- Desipramine: Another tricyclic antidepressant that is structurally related to Demexiptiline.
External links
- Medical encyclopedia article on Demexiptiline
- Wikipedia's article - Demexiptiline
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski